Compare
Alpha Cognition Inc. vs TScan Therapeutics, Inc. vs Taysha Gene Therapies, Inc. vs Caribou Biosciences, Inc.
| Latest fiscal year | Alpha Cognition Inc. ACOG | TScan Therapeutics, Inc. TCRX | Taysha Gene Therapies, Inc. TSHA | Caribou Biosciences, Inc. CRBU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $10.22M | $10.32M | $9.77M | $11.16M |
| Revenue growth (YoY) | n/a | +266.7% | +17.3% | +11.7% |
| Gross margin | 94.1% (computed) | n/a | n/a | n/a |
| Operating margin | -221.7% | n/m | n/m | n/m |
| Net margin | -202.2% | n/m | n/m | n/m |
| Net income | -$20.67M | -$129.77M | -$109.00M | -$148.12M |
| EPS (Diluted) | -$1.18 | -$1.00 | -$0.34 | -$1.59 |
| Operating cash flow | -$20.38M | -$135.32M | -$93.09M | -$110.99M |
| Free cash flow | -$20.67M | -$139.73M | -$93.83M | -$112.35M |
| Cash & equivalents | $66.05M | $152.41M | $319.77M | $12.36M |
| Total assets | $79.73M | $228.79M | $343.32M | $175.37M |
| Total liabilities | $17.20M | $105.67M | $96.38M | $53.19M |
| Shareholders' equity | $62.53M | $123.12M | $246.94M | $122.17M |
| Return on year-end equity | -33.1% | -105.4% | -44.1% | -121.2% |
| Shares outstanding | 21.74M | n/a | 285.05M | 95.14M |
Revenue, most recent five fiscal years
| Fiscal year | Alpha Cognition Inc. | TScan Therapeutics, Inc. | Taysha Gene Therapies, Inc. | Caribou Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $10.22M Ended 2025-12-31 | $10.32M Ended 2025-12-31 | $9.77M Ended 2025-12-31 | $11.16M Ended 2025-12-31 |
| 1 year earlier | n/a | $2.82M Ended 2024-12-31 | $8.33M Ended 2024-12-31 | $9.99M Ended 2024-12-31 |
| 2 years earlier | n/a | $21.05M Ended 2023-12-31 | $15.45M Ended 2023-12-31 | $34.48M Ended 2023-12-31 |
| 3 years earlier | n/a | $13.54M Ended 2022-12-31 | $2.50M Ended 2022-12-31 | $13.85M Ended 2022-12-31 |
| 4 years earlier | n/a | $10.14M Ended 2021-12-31 | n/a | $9.60M Ended 2021-12-31 |